MedMira Receives Investigational Testing Authorizations for Multiplo® TP/HIV Self-Test and Non-Professional Use Applications

Halifax, Nova Scotia, 21st of January, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received Investigational Testing Authorizations (ITAs) from Health Canada to begin clinical trials for new label claim applications of its recently Health Canada approved Multiplo® TP/HIV rapid test. These applications include use as a self-test and for non-professional […]
MedMira receives investigational testing authorization for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test

Halifax, Nova Scotia, 9 January, 2025 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announced that its received investigational testing authorization (ITA) from Health Canada to begin clinical trials for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP), a cutting edge device that can determine active and non-active syphilis. The upcoming trials will be led […]